{"filing":{"accession_number":"0001104659-26-093710","cik":"0001720893","ticker":"BTAI","company_name":"BioXcel Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-10","primary_document":"tm2622818d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926093710/tm2622818d1_8k.htm"},"events":[{"id":26835,"run_id":24406,"accession_number":"0001104659-26-093710","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"summary":"BioXcel entered into the Twelfth Amendment to its Credit Agreement on August 10, 2026, modifying existing debt terms. While this is technically an amendment to an existing credit facility rather than issuance of new debt, the filing is disclosed under Item 1.01 (Material Definitive Agreement). However, the substance here is a covenant modification and extension of a deadline to refinance or execute an alternative capital transaction—signaling financial stress and potential covenant breach risk rather than new debt creation. The requirement to refinance by August 21, 2026, and the reduction of minimum liquidity from $6.25M to $3.0M suggest the company is under pressure to restructure its capital.","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28107,"accession_number":"0001104659-26-093710","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"BioXcel entered into the Twelfth Amendment to its Credit Agreement on August 10, 2026, modifying existing debt terms. While this is technically an amendment to an existing credit facility rather than issuance of new debt, the filing is disclosed under Item 1.01 (Material Definitive Agreement). However, the substance here is a covenant modification and extension of a deadline to refinance or execute an alternative capital transaction—signaling financial stress and potential covenant breach risk rather than new debt creation. The requirement to refinance by August 21, 2026, and the reduction of minimum liquidity from $6.25M to $3.0M suggest the company is under pressure to restructure its capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:02:20.955355+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28107,"accession_number":"0001104659-26-093710","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"BioXcel entered into the Twelfth Amendment to its Credit Agreement on August 10, 2026, modifying existing debt terms. While this is technically an amendment to an existing credit facility rather than issuance of new debt, the filing is disclosed under Item 1.01 (Material Definitive Agreement). However, the substance here is a covenant modification and extension of a deadline to refinance or execute an alternative capital transaction—signaling financial stress and potential covenant breach risk rather than new debt creation. The requirement to refinance by August 21, 2026, and the reduction of minimum liquidity from $6.25M to $3.0M suggest the company is under pressure to restructure its capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:02:20.955355+00:00","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-08-11"}]}